top of page

Press releases

April 23, 2024

October 10, 2023

Thermedical Awarded $3 Million NIH Grant to Study Promising Treatment for Ventricular Tachycardia, a Leading Cause of Sudden Cardiac Death

Thermedical Successfully Completes PFA Feasibility Study

August 22, 2022

Thermedical Announces FDA Approval of Clinical Trial for SERF Ablation to Treat Patients with Ventricular Tachycardia, Leading Cause of Sudden Cardiac Death

June 18, 2020

May 18, 2020

May 8, 2020

July 31, 2018

March 20, 2018

October 31, 2012

October 27, 2006

The Thermedical® Ablation System is 510(k) cleared for the coagulation and ablation of soft tissue during percutaneous, laparoscopic and intraoperative surgical procedures.  Use of the Thermedical Ablation System for any specific soft tissue indication has not been evaluated or approved by the US FDA.

Use of the Thermedical Ablation System for the treatment of VT is investigational and is not approved for use or sale in any market.

150 Bear Hill Road,  Waltham, MA 02451-1036
781.373.3688

©Copyright Thermedical, Inc. 2011-2015. All Rights Reserved. | Copyright and Trademark Notice 
Thermedical® and Durablateâ„¢ are trademarks of Thermedical, Inc. registered in the United States and Internationally.

bottom of page